INT4807

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1989
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 23
Total Number 23
Disease Relevance 6.89
Pain Relevance 7.59

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (LTC4S) nuclear envelope (LTC4S) small molecule metabolic process (LTC4S)
lyase activity (LTC4S) endoplasmic reticulum (LTC4S) nucleus (LTC4S)
Anatomy Link Frequency
basophils 5
mast cells 5
skin 2
PGE2 2
joint 1
LTC4S (Homo sapiens)
Pain Link Frequency Relevance Heat
Buprenorphine 18 99.28 Very High Very High Very High
Morphine 21 98.98 Very High Very High Very High
Opioid 24 98.78 Very High Very High Very High
Inflammation 21 98.64 Very High Very High Very High
antagonist 14 98.00 Very High Very High Very High
rheumatoid arthritis 9 97.80 Very High Very High Very High
Osteoarthritis 3 96.04 Very High Very High Very High
aspirin 43 95.04 Very High Very High Very High
cINOD 24 93.64 High High
dexamethasone 3 90.80 High High
Disease Link Frequency Relevance Heat
Arthropathy 7 99.32 Very High Very High Very High
INFLAMMATION 36 98.64 Very High Very High Very High
Rheumatoid Arthritis 9 97.80 Very High Very High Very High
Anaphylactic Hypersensitivity 1 97.28 Very High Very High Very High
Chondrocalcinosis 3 96.80 Very High Very High Very High
Hypersensitivity 5 96.48 Very High Very High Very High
Osteoarthritis 3 96.04 Very High Very High Very High
Asthma 67 92.56 High High
Disease 15 91.72 High High
Anaphylaxis 3 86.60 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Calcium ionophore A23187 significantly increased the release of PGE2, 6-keto-PGF1 alpha, LTB4, and LTC4 from human synovial tissue irrespective of the underlying joint disease.
Localization (release) of LTC4 in joint associated with arthropathy
1) Confidence 0.58 Published 1991 Journal Wien. Klin. Wochenschr. Section Abstract Doc Link 1673814 Disease Relevance 0.50 Pain Relevance 0.19
The effects of increasing concentrations of three opioids (morphine, buprenorphine, and fentanyl) were studied on the release of preformed (histamine and tryptase) and de novo synthesized (prostaglandin D2 [PGD2] and peptide-leukotriene C4 [LTC4]) chemical mediators from human peripheral blood basophils and mast cells isolated from skin tissues or lung parenchyma.
Localization (release) of peptide-leukotriene C4 in basophils associated with opioid, buprenorphine and morphine
2) Confidence 0.57 Published 1992 Journal Anesthesiology Section Abstract Doc Link 1280014 Disease Relevance 0 Pain Relevance 0.74
The effects of increasing concentrations of three opioids (morphine, buprenorphine, and fentanyl) were studied on the release of preformed (histamine and tryptase) and de novo synthesized (prostaglandin D2 [PGD2] and peptide-leukotriene C4 [LTC4]) chemical mediators from human peripheral blood basophils and mast cells isolated from skin tissues or lung parenchyma.
Localization (release) of LTC4 in basophils associated with opioid, buprenorphine and morphine
3) Confidence 0.57 Published 1992 Journal Anesthesiology Section Abstract Doc Link 1280014 Disease Relevance 0 Pain Relevance 0.75
Maximal stimulation of HHMC with anti-IgE led to the release of LTC4 (17.5 +/- 5.1 ng/10(6) mast cells) and PGD2 (17.8 +/- 5.0 ng/10(6) mast cells, whereas HSMC synthesized more PGD2 (65.0 +/- 6.8 ng/10(6) mast cells) and much less LTC4 (< 5 ng/10(6) cells).
Localization (release) of LTC4 in HSMC
4) Confidence 0.56 Published 1995 Journal Int. Arch. Allergy Immunol. Section Abstract Doc Link 7536502 Disease Relevance 0.27 Pain Relevance 0.18
Cross-linking of the high-affinity receptor for IgE (Fc epsilon RI) by a polyclonal anti-Fc epsilon antibody caused the release of preformed (histamine and tryptase) and de novo synthesized mediators [peptide leukotriene C4 (LTC4) and prostaglandin D2 (PGD2)].
Localization (release) of peptide leukotriene C4
5) Confidence 0.56 Published 1995 Journal Int. Arch. Allergy Immunol. Section Abstract Doc Link 7536502 Disease Relevance 0.34 Pain Relevance 0.16
Cross-linking of the high-affinity receptor for IgE (Fc epsilon RI) by a polyclonal anti-Fc epsilon antibody caused the release of preformed (histamine and tryptase) and de novo synthesized mediators [peptide leukotriene C4 (LTC4) and prostaglandin D2 (PGD2)].
Localization (release) of LTC4
6) Confidence 0.56 Published 1995 Journal Int. Arch. Allergy Immunol. Section Abstract Doc Link 7536502 Disease Relevance 0.34 Pain Relevance 0.16
None of the drugs tested induced the release of histamine or LTC4 from basophils of normal donors.
Localization (release) of LTC4 in basophils
7) Confidence 0.55 Published 1993 Journal Ann Fr Anesth Reanim Section Abstract Doc Link 7690200 Disease Relevance 0 Pain Relevance 0.37
SASP inhibited release of LTC4 and increased release of PGE2.
Localization (release) of LTC4
8) Confidence 0.51 Published 1991 Journal Wien. Klin. Wochenschr. Section Abstract Doc Link 1673814 Disease Relevance 0.51 Pain Relevance 0.19
We investigated the effects of NIM and of its in vivo metabolite, 4-hydroxy-NIM (OH-NIM), on the release of performed (histamine) and de novo synthesized mediators (sulfidopeptide leukotriene C4 [LTC4] and prostaglandin D2 [PGD2]) from human basophils and mast cells isolated from lung parenchyma (HLMC) and skin (HSMC).
Localization (release) of LTC4 in mast cells
9) Confidence 0.47 Published 1993 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 7505332 Disease Relevance 0.35 Pain Relevance 0.53
We investigated the effects of NIM and of its in vivo metabolite, 4-hydroxy-NIM (OH-NIM), on the release of performed (histamine) and de novo synthesized mediators (sulfidopeptide leukotriene C4 [LTC4] and prostaglandin D2 [PGD2]) from human basophils and mast cells isolated from lung parenchyma (HLMC) and skin (HSMC).
Localization (release) of leukotriene C4 in mast cells
10) Confidence 0.47 Published 1993 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 7505332 Disease Relevance 0.35 Pain Relevance 0.53
SASP inhibited release of LTC4 and increased release of PGE2.
Localization (release) of LTC4
11) Confidence 0.45 Published 1991 Journal Wien. Klin. Wochenschr. Section Abstract Doc Link 1673814 Disease Relevance 0.51 Pain Relevance 0.20
Histamine and immunoreactive LTC4 and PGD2 release was monitored in all experiments.
Localization (release) of LTC4
12) Confidence 0.42 Published 1989 Journal Am. Rev. Respir. Dis. Section Abstract Doc Link 2478059 Disease Relevance 0.14 Pain Relevance 0.19
The recent development of in vitro techniques to study the release of preformed (histamine and tryptase) and de novo synthesized mediators (PGD2, LTC4, and PAF) from purified basophils and mast cells has made it possible to quantify the mediator-releasing activity of anesthetics such as muscle relaxants, general anesthetics, opioids, and benzodiazepines and RCM on human basophils and mast cells isolated from lung, skin and heart tissues.
Localization (release) of LTC4 in skin associated with opioid
13) Confidence 0.36 Published 1996 Journal Int. Arch. Allergy Immunol. Section Abstract Doc Link 8645973 Disease Relevance 0.16 Pain Relevance 0.09
Under these conditions, PGE2, 6-keto-PGF1alpha, and LTC4 release from synovial tissue was detectable only after stimulation with calcium ionophore A23187.
Localization (release) of LTC4 in PGE2
14) Confidence 0.27 Published 1998 Journal Acta Orthop Scand Section Abstract Doc Link 9703407 Disease Relevance 0.30 Pain Relevance 0.08
The LTC4 is secreted from mast cells following Ca(2+) influx through store-operated calcium release-activated calcium (CRAC) channels [7-10].
Localization (secreted) of LTC4 in mast cells
15) Confidence 0.23 Published 2010 Journal BMC Med Genet Section Body Doc Link PMC2954844 Disease Relevance 1.23 Pain Relevance 0.27
Concentrations of leukotriene B4 (LTB4, LTC4, and thromboxane B2 (TXB2) were measured in blood before and after oral administration of tepoxalin and release of prostaglandin E2 (PGE2), 6-keto-PGF1alpha, and LTC4 was measured in incubation media of synovial tissue, taken at surgery from patients treated with tepoxalin.
Localization (release) of LTC4 in PGE2
16) Confidence 0.20 Published 1998 Journal Acta Orthop Scand Section Abstract Doc Link 9703407 Disease Relevance 0.29 Pain Relevance 0.05
The effects of increasing concentrations of three opioids (morphine, buprenorphine, and fentanyl) were studied on the release of preformed (histamine and tryptase) and de novo synthesized (prostaglandin D2 [PGD2] and peptide-leukotriene C4 [LTC4]) chemical mediators from human peripheral blood basophils and mast cells isolated from skin tissues or lung parenchyma.
Localization (release) of LTC4 in mast cells associated with opioid, buprenorphine and morphine
17) Confidence 0.19 Published 1992 Journal Anesthesiology Section Abstract Doc Link 1280014 Disease Relevance 0 Pain Relevance 0.75
The effects of increasing concentrations of three opioids (morphine, buprenorphine, and fentanyl) were studied on the release of preformed (histamine and tryptase) and de novo synthesized (prostaglandin D2 [PGD2] and peptide-leukotriene C4 [LTC4]) chemical mediators from human peripheral blood basophils and mast cells isolated from skin tissues or lung parenchyma.
Localization (release) of peptide-leukotriene C4 in mast cells associated with opioid, buprenorphine and morphine
18) Confidence 0.19 Published 1992 Journal Anesthesiology Section Abstract Doc Link 1280014 Disease Relevance 0 Pain Relevance 0.74
We investigated the effects of NIM and of its in vivo metabolite, 4-hydroxy-NIM (OH-NIM), on the release of performed (histamine) and de novo synthesized mediators (sulfidopeptide leukotriene C4 [LTC4] and prostaglandin D2 [PGD2]) from human basophils and mast cells isolated from lung parenchyma (HLMC) and skin (HSMC).
Localization (release) of leukotriene C4 in basophils
19) Confidence 0.16 Published 1993 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 7505332 Disease Relevance 0.35 Pain Relevance 0.53
We investigated the effects of NIM and of its in vivo metabolite, 4-hydroxy-NIM (OH-NIM), on the release of performed (histamine) and de novo synthesized mediators (sulfidopeptide leukotriene C4 [LTC4] and prostaglandin D2 [PGD2]) from human basophils and mast cells isolated from lung parenchyma (HLMC) and skin (HSMC).
Localization (release) of LTC4 in basophils
20) Confidence 0.16 Published 1993 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 7505332 Disease Relevance 0.35 Pain Relevance 0.53

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox